Piritrexim isethionate | 79483-69-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: Piritrexim isethionate
• 英文别名: 6-[(2,5-dimethoxyphenyl)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine;2-hydroxyethanesulfonic acid
• CAS: 79483-69-5
• 化学式: C19H25N5O6S
• 分子量: 451.5
• InChiKey: IOEMETRLOWNXGW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.97
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  192
• 氢给体数：
  4
• 氢受体数：
  11

文献信息

• COMPOSITIONS OF COMPOUNDS AND USES THEREOF
  申请人：VM Oncology LLC

  公开号：US20150218132A1

  公开（公告）日：2015-08-06

  The present disclosure relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same. The disclosure further concerns the use of such compounds in the treatment and/or prevention of certain types of cancers, pain, inflammation, restenosis, atherosclerosis, psoriasis, thrombosis, Alzheimer's, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination.

  本公开涉及新型合成取代杂环化合物和含有这些化合物的药物组合物。该公开进一步涉及利用这些化合物治疗和/或预防某些类型的癌症、疼痛、炎症、再狭窄、动脉粥样硬化、牛皮癣、血栓形成、阿尔茨海默病、与失髓鞘形成或脱髓鞘有关的疾病、紊乱、损伤或功能障碍。
• [EN] CRYSTALLINE FORMS OF TYROSINE KINASE INHIBITORS AND THEIR SALTS<br/>[FR] FORMES CRISTALLINES D'INHIBITEURS DE LA TYROSINE KINASE ET LEURS SELS
  申请人：VM PHARMA LLC

  公开号：WO2016043975A1

  公开（公告）日：2016-03-24

  The disclosure relates to various polymorphic forms and amorphous form of sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzoate, including the polymorphic form A, mixtures of the polymorphs, process for the preparation thereof and the use thereof in a pharmaceutical composition containing thereof.

  该披露涉及钠4-((3-(4-环己基哌嗪-1-基)-6-氧代-6H-蒽[1,9-cd]异噁唑-5-基)氨基)苯甲酸的各种多形态和非晶形态，包括多形态A、多形态的混合物，其制备方法以及在含有该物质的药物组合物中的使用。
• [EN] FORMYLATED N-HETEROCYCLIC DERIVATIVES AS FGFR4 INHIBITORS<br/>[FR] DÉRIVÉS N-HÉTÉROCYCLIQUES FORMYLÉS UTILISÉS EN TANT QU'INHIBITEURS DE FGFR4
  申请人：NOVARTIS AG

  公开号：WO2016151499A1

  公开（公告）日：2016-09-29

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

  本发明提供了化合物(I)或其药学上可接受的盐；(I)制造该化合物的方法及其治疗用途。本发明还提供了药理活性剂的组合物和包含该化合物的药物组合物。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• [EN] DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF<br/>[FR] LIQUIDES IONIQUES À DOUBLE FONCTION ET SELS DE CEUX-CI
  申请人：UNIV ALABAMA

  公开号：WO2010078300A1

  公开（公告）日：2010-07-08

  Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are 'solvated,' for example, 'hydrated' and their uses.

  本文揭示了包括活性药物、生物学和营养化合物的离子液体组合物，以及其使用方法。进一步揭示了包括液态离子对的物质组合物，单独或溶解后使用；以及离子液体的“溶剂化”组合物，例如“水合”的组合物及其用途。